ArticleThe journal of international advanced otology2021
The Effectiveness of Hyperbaric Oxygen Therapy in Severe Idiopathic Sudden Sensorineural Hearing Loss.
Article in The journal of international advanced otology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Semicircular canal dysfunction in profound sudden sensorineural hearing loss and its prognostic value: implications for the proper indication of hyperbaric oxygen therapy.Scientific reports · 2026Article
- Impact of Hyperbaric Oxygen Therapy on Recovery in Patients With Sudden Sensorineural Hearing Loss: An Observational Study.Journal of audiology & otology · 2025Article
- Hyperbaric oxygen therapy improves the effects of systemic steroid therapy for sudden sensorineural hearing loss.Heliyon · 2025Article
- Article
- Hyperbaric Oxygen Therapy in the Treatment of Sudden Sensorineural Hearing Loss.Journal of clinical medicine · 2023Article
- Research progress on the treatment and nursing of sensorineural hearing loss.Frontiers in neuroscience · 2023Review
- Idiopathic Sudden Sensorineural Hearing Loss: Is Hyperbaric Oxygen Treatment the Sooner and Longer, the Better?Journal of personalized medicine · 2022Article
- Circulatory disturbance of the cochlear spiral modiolar artery in a type 2 diabetic mouse model.Laryngoscope investigative otolaryngology · 2022Article
- Article
- Hyperbaric Protocols for Idiopathic Sudden Sensorineural Hearing Loss.The journal of international advanced otology · 2021Article
- Impact of hyperbaric oxygen as initial treatment on idiopathic sudden sensorineural hearing loss prognosis: a propensity scores matching analysis.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of combined hyperbaric oxygen therapy (HBOT) and steroid therapy in severe idiopathic sudden sensorineural hearing loss (ISSNHL).
methodsBetween January 2010 and July 2017, we evaluated 218 patients with ISSNHL and divided them into 2 groups: those with hearing loss greater than 80 dB and those with hearing loss of 60-79 dB. Each group was further divided into 3 groups according to the treatment method: oral steroids alone (PO), PO+intratympanic injection (IT), and PO+IT+HBOT. The treatment effect was evaluated for improvement in hearing thresholds at mid-term (3 weeks later) and final term (2 months later).
resultsWhen comparing the 3 treatment groups within the group that had a hearing loss greater than 80 dB, no differences were observed in the gaps in hearing thresholds and in the duration of improvement (P = .0764 and .2938, respectively). However, in the group with 60-79 dB hearing loss, the gaps in hearing thresholds at mid-term were 27.50 dB in the PO group, 38.13 dB in the PO+IT group, and 51.25 dB in the PO+IT+HBOT group. The treatment was more effective and faster in the initial period in the PO+IT+HBOT group than in the other groups. In addition, the results of frequency analysis showed greatest treatment efficacy at low frequencies of hearing.
conclusionPatients with ISSNHL above 80 dB are less likely to recover hearing even after PO+IT+HBOT. However, this treatment initially accelerates recovery in patients with a hearing loss below 80 dB. Therefore, the appropriate indication for HBOT benefits in patients with severe or profound ISSNHL should be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.